Treatment options following metformin in primary prevention populations with type 2 diabetes: which is the right road to take?

References

• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487–493.
   PubMed Web of Science ®Google Scholar
• Koufakis T, Dimitriadis G, Kotsa K. A lion in the room: has the CAROLINA trial definitely resolved the issue of the cardiovascular safety of sulfonylureas? J Diabetes. 2020;12:499–502.
   PubMed Web of Science ®Google Scholar
• Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Curr Diab Rep. 2019;19:151.
   PubMed Web of Science ®Google Scholar
• Buse JB, Bain SC, Mann JFE, et al. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial. Diabetes Care. 2020;43:1546–1552.
   PubMed Web of Science ®Google Scholar
• Munir KM, Davis SN. Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes? Expert Opin Pharmacother. 2018;19:773–777.
   PubMed Web of Science ®Google Scholar
• Kyriakidou A, Koufakis T, Goulis DG, et al. Pharmacogenetics of the glucagon-like peptide-1 receptor agonist liraglutide: a step towards personalized type 2 diabetes management. Curr Pharm Des. 2021;27:1025–1034.
   PubMed Web of Science ®Google Scholar
• Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37:1650–1659.
   PubMed Web of Science ®Google Scholar
• Knudsen JS, Baggesen LM, Lajer M, et al. Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: a Danish nationwide population-based study. PLoS One. 2020;15:e0229621.
   PubMed Web of Science ®Google Scholar
• Spain CV, Wright JJ, Hahn RM, et al. Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin Ther. 2016;38:1653–1664.e1.
   PubMed Web of Science ®Google Scholar
• Weiss T, Carr RD, Pal S, et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Patient Prefer Adherence. 2020;14:2337–2345.
   PubMed Web of Science ®Google Scholar
• Dubrofsky L, Srivastava A, Cherney DZ. Sodium-glucose cotransporter-2 inhibitors in nephrology practice: a narrative review. Can J Kidney Health Dis. 2020;7:2054358120935701.
   Google Scholar
• Shehadeh N, Raz I, Nakhleh A. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease. Cardiovasc Diabetol. 2018;17:117.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Son YJ. Prevalence and associated factors of frailty and mortality in patients with end-stage renal disease undergoing hemodialysis: a systematic review and meta-analysis. Int J Environ Res Public Health. 2021;18:3471.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Shehadeh N, Ametov AS, et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19:185.
   PubMed Web of Science ®Google Scholar
• Szczech LA, Stewart RC, Su HL, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PLoS One. 2014;9:e110535.
   PubMed Web of Science ®Google Scholar
• Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2020;173:278–286.
   PubMed Web of Science ®Google Scholar
• Arnott C, Li Q, Kang A, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9:e014908.
   PubMed Web of Science ®Google Scholar
• Cahn A, Raz I, Leiter LA, et al. Cardiovascular, renal, and metabolic outcomes of dapagliflozin versus placebo in a primary cardiovascular prevention cohort: analyses from DECLARE-TIMI 58. Diabetes Care. 2021;44(5):1159–1167.
   PubMed Web of Science ®Google Scholar
• Koufakis T, Papanas N, Dimitriadis G, et al. Interpreting the results of the VERTIS-CV trial: is this the end of the “class effect” perspective? J Diabetes. 2020;12:942–945.
   PubMed Web of Science ®Google Scholar
• Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776–785.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–130.
   PubMed Web of Science ®Google Scholar
• Arnold SV, Echouffo-Tcheugui JB, Lam CSP, et al. Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). Am Heart J. 2018;203:25–29.
   PubMed Web of Science ®Google Scholar
• Bajpai S, Wong-Jacobson S, Liu D, et al. Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States. J Manag Care Spec Pharm. 2021;27:385–391.
   PubMed Web of Science ®Google Scholar